Broadcom named strategic vendor for Walmart virtualization solutions
Investing.com - D. Boral (OTC:BOALY) Capital has reiterated its Buy rating on Artelo Biosciences , Inc. (NASDAQ:ARTL) with a price target of $20.00, representing a 100% upside from the current price of $10.01. According to InvestingPro data, the stock has shown significant volatility, gaining over 45% in the past six months despite a recent 27% weekly decline.
The firm highlighted upcoming catalysts for the biopharmaceutical company, noting Artelo is preparing to launch a Phase 1 clinical trial for its ART12.11 candidate in early 2026.
D. Boral Capital pointed out the trial may include Innovative Licensing and Access Pathway (ILAP) designation if formally accepted by UK authorities, which could enable faster clinical development, enhanced regulatory guidance, and potential early access in the UK market.
The research firm also mentioned Artelo continues to advance discussions with regulators and potential partners across its broader pipeline of products.
According to D. Boral Capital, ART12.11’s novel mechanism and patent coverage through 2038 position it as a high-value asset in the neuropsychiatric space.
In other recent news, Artelo Biosciences announced a $9.475 million private placement to implement a Solana-based treasury strategy. This makes Artelo the first publicly-traded pharmaceutical company to use Solana’s cryptocurrency as a core reserve asset. The company also received favorable guidance from the UK’s Medicines and Healthcare products Regulatory Agency for its Phase 1 trial of the CBD:TMP cocrystal, designed for treating anxiety and depression. This guidance includes a streamlined clinical trial application process for ART12.11. Additionally, Artelo Biosciences completed a one-for-six reverse stock split, reducing its outstanding common shares from approximately 3,280,000 to about 546,667. Preliminary unaudited financial estimates for the quarter ending June 30, 2025, indicate cash, cash equivalents, and short-term investments of $2.1 million, with working capital estimated between negative $1.2 million and negative $1.5 million. Furthermore, the company presented positive preclinical data for its FABP5 inhibitor, ART26.12, which showed significant pain relief in osteoarthritis models. The data was presented at the 35th Annual International Cannabinoid Research Society Symposium.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.